Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK | Market Cap | 19.75B -54.2% |
| Revenue (ttm) | 9.21B +14,598.9% |
| Net Income | 6.46B |
| EPS | 90.22 |
| Shares Out | 70.61M |
| PE Ratio | 3.10 |
| Forward PE | 15.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 348,415 |
| Average Volume | 542,685 |
| Open | 282.00 |
| Previous Close | 280.50 |
| Day's Range | 276.10 - 288.10 |
| 52-Week Range | 233.50 - 588.00 |
| Beta | 0.42 |
| RSI | 36.70 |
| Earnings Date | Feb 19, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
Financial StatementsNews
Zealand Pharma A/S at Barclays Global Healthcare Conference Transcript
Zealand Pharma A/S at Barclays Global Healthcare Conference Transcript
Zealand Pharma to participate in upcoming investor conferences in March 2026
Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly
Roche and Zealand Pharma's obesity drug petrelintide showed up to 11% weight loss in a Phase 2 trial with strong safety results. ... Full story available on Benzinga.com
Zealand Pharma slump wipes billions off its value after obesity drug data disappoints
Shares in Zealand Pharma tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity drug petrelintide fe...
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living w...
Q4 2025 Zealand Pharma A/S Earnings Call Transcript
Q4 2025 Zealand Pharma A/S Earnings Call Transcript
Zealand Pharma convenes its Annual General Meeting 2026
Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEA...
Zealand Pharma Announces Financial Results for the Full Year 2025
Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide,...
Zealand Pharma Reports Positive Phase 1a Results For Kv1.3 Channel Blocker ZP9830
(RTTNews) - Zealand Pharma A/S (ZEAL) announced positive topline results from its Phase 1a clinical trial of ZP9830, a Kv1.3 channel blocker.
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
Press release – No. 4 / 2026 Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse ...
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results
Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (...
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmar...
Total number of shares and voting rights in Zealand Pharma as of December 31, 2025
Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Z...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand P...
Zealand Pharma to accelerate drug development for obesity, metabolic disease
Danish biotech Zealand Pharma said on Thursday it will accelerate development and expand its research as it seeks to differentiate its experimental obesity drug candidates in an increasingly competiti...
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10...
Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration w...
REMINDER: Zealand Pharma's Capital Markets Day on December 11, 2025
Press release – No. 17 / 2025 REMINDER: Zealand Pharma's Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Zealand Pharma is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an...
Zealand Pharma Announces Financial Results for the First Nine Months of 2025
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025 With petrelintide advancing at full speed and topline data rapidly approaching for bot...
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
Press release – No. 16 / 2025 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 12, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results
Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand Pharma A...